52334-79-9 Usage
General Description
3-AMINO-6-METHYLPYRIDIN-2-OL, also known as 6-methyl-2-pyridinamine, is a chemical compound with the molecular formula C6H8N2O. It is a derivative of pyridine and contains an amino group and a hydroxyl group on the 2 and 6 positions of the pyridine ring, respectively. 3-AMINO-6-METHYLPYRIDIN-2-OL is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules, including pharmaceutical drugs and agrochemicals. 3-AMINO-6-METHYLPYRIDIN-2-OL also has potential applications in the development of materials science, such as in the production of organic light-emitting diodes (OLEDs) and other electronic devices.
Check Digit Verification of cas no
The CAS Registry Mumber 52334-79-9 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,3,3 and 4 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 52334-79:
(7*5)+(6*2)+(5*3)+(4*3)+(3*4)+(2*7)+(1*9)=109
109 % 10 = 9
So 52334-79-9 is a valid CAS Registry Number.
InChI:InChI=1/C6H8N2O/c1-4-2-3-5(7)6(9)8-4/h2-3H,7H2,1H3,(H,8,9)
52334-79-9Relevant articles and documents
Identification of the First Synthetic Allosteric Modulator of the CB2 Receptors and Evidence of Its Efficacy for Neuropathic Pain Relief
Gado, Francesca,Di Cesare Mannelli, Lorenzo,Lucarini, Elena,Bertini, Simone,Cappelli, Elena,Digiacomo, Maria,Stevenson, Lesley A.,Macchia, Marco,Tuccinardi, Tiziano,Ghelardini, Carla,Pertwee, Roger G.,Manera, Clementina
, p. 276 - 287 (2018/07/21)
The direct activation of cannabinoid receptors (CBRs) results in several beneficial effects; therefore several CBRs ligands have been synthesized and tested in vitro and in vivo. However, none of them reached an advanced phase of clinical development due
HETEROCYCLIC DERIVATIVES
-
Page/Page column 17, (2011/02/25)
The present invention relates to heterocyclic derivatives, and more particularly, to novel heterocyclic derivatives useful for the preparation of medicaments for treating diseases related to uric acid.
